Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC28-E for Moderate to Severe Nonproliferative Diabetic Retinopathy
CTR20202586Phase 2Completed
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eflimrufusp alfa in diabetic retinopathy (DR), sponsored by Rongchang Pharmaceuticals. Started Mar 2021; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on CTR20202586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202586.